[Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect

2026 is framed as a pivotal turning point for the pharmaceutical industry. The market is being reshaped by three concurrent forces: Merck’s Keytruda sustaining its immuno-oncology dominance, the rapid ascent of Eli Lilly and Novo Nordisk’s “diabesity” portfolios redefining the value center of the industry, and the first real financial impact of the U.S. Inflation Reduction Act (IRA) as negotiated “Maximum Fair Prices” (MFPs) take effect on January 1. Together, these developments are altering pricing expectations, portfolio strategy, and competitive positioning across the global top-selling drug franchises.

A New U.S. Pricing Reality: IRA Maximum Fair Prices Begin, Rewriting the Rules of Drug Pricing

Starting January 1, 2026, the IRA’s negotiated Maximum Fair Prices formally take effect, marking a structural shift in how drugs are priced within U.S. government channels. Among the first wave of negotiated products are Eliquis and Jardiance. The expected price reductions ranging from roughly 38% to nearly 70%, a level of discounting that directly lowers revenue ceilings for mature brands and signals an end to the era of unconstrained pricing for selected high-spend therapies.

The implications extend beyond near-term revenue pressure. The IRA introduces a material distinction in lifecycle economics: biologics receive 13 years of negotiation exemption after launch, while small molecules receive 9 years. In 2026, that gap is influencing R&D prioritization and asset valuation, nudging companies toward biologics where longer protected commercial windows can better absorb development costs and sustain returns before government price negotiation risk becomes immediate.

However, this new environment creates heightened risk for certain franchises. Johnson & Johnson’s Stelara as a cautionary case of “double cliff” exposure. The drug faces simultaneous pressure from IRA-driven price reductions and the market entry of biosimilars, combining government pricing intervention with competitive erosion. This convergence is described as a warning for the sector, pushing manufacturers to rethink product lifecycle strategy—placing greater emphasis on maximizing value earlier in a product’s commercial arc rather than relying on prolonged, late-stage revenue plateaus.

Diabesity Redefines Industry Priorities: Novo Nordisk vs. Lilly and the Metabolic “Capital Supercycle”

2026 cements metabolic disease as the industry’s third major pillar alongside oncology and immunology. GLP-1–based therapies are positioned as the engine of a broader “capital supercycle,” with Novo Nordisk and Eli Lilly’s expanding market capitalizations enabling outsized investment capacity in R&D and M&A. That capital migration is described as creating a “halo effect,” channeling profits into adjacent comorbidity areas including heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and metabolic dysfunction–associated steatohepatitis (MASH).

On strategy, Novo Nordisk is presented as leveraging first-mover advantage and large-scale cardiovascular and renal outcomes data to build a defensible clinical moat. Take the SELECT and FLOW studies as pivotal, elevating Ozempic and Wegovy beyond glucose control and weight loss into higher-value positioning tied to cardiovascular event prevention and slowing renal disease progression. This shift strengthens the company’s negotiating posture with payers by anchoring pricing discussions in outcomes-driven value rather than symptomatic improvement alone, helping offset rising price pressure with sustained volume growth.

Eli Lilly, by contrast, is portrayed as advancing primarily on superior efficacy. As the first dual GIP/GLP-1 agonist, Mounjaro and Zepbound are described as delivering stronger glycemic and weight-loss outcomes than semaglutide in clinical trials, enabling an aggressive clinical push and rapid global expansion. Manufacturing and supply buildout as a critical pillar of Lilly’s approach, aimed at meeting fast-growing demand and converting clinical advantage into sustained market share.

A notable nuance concerns brand reporting versus molecule value. If Mounjaro (diabetes) and Zepbound (obesity) are combined, tirzepatide’s 2026 sales are estimated at $33–$38 billion—technically exceeding Keytruda at the molecule level. However, because the products are reported as distinct commercial brands, rankings that track individual brands still place Mounjaro as No. 3 rather than naming tirzepatide as the overall sales leader.

Peak Franchise, Defensive Pivot: Keytruda’s Countdown and Immunology’s Accelerating Generational Shift

In immuno-oncology, Keytruda remains the projected global sales leader in 2026, with revenue exceeding $30 billion, attributes much of the continued growth to deeper penetration in adjuvant (post-surgical) and neoadjuvant (pre-surgical) settings. These earlier-stage markets are characterized as commercially attractive due to defined treatment courses and higher survival rates, supporting a large, durable patient base and steadier growth dynamics.

At the same time, it was underscored how Keytruda’s scale amplifies company-level concentration risk. With projected 2026 revenue estimated to represent roughly 45% to 50% of Merck’s total pharmaceutical revenue, the franchise’s trajectory materially shapes corporate decision-making across business development and R&D investment. The looming U.S. patent cliff in late 2028 is described as a central strategic constraint, influencing actions taken well in advance.

Merck’s primary lifecycle defense is development of a subcutaneous formulation. Compared with multi-hour IV infusions, subcutaneous delivery can be administered in minutes—an operational advantage frames as a classic defensive move designed to transition patients to a new formulation with extended protection and improve retention once biosimilars enter the market.

In immunology, it is described as an accelerating shift toward more targeted mechanisms. Dupixent is positioned as a “pipeline in a product,” using IL-4/IL-13 inhibition to span multiple type 2 inflammatory diseases, with a COPD launch characterized as a key 2026 growth catalyst. Skyrizi is portrayed as AbbVie’s most successful Humira successor, combining high efficacy with a convenient maintenance dosing interval (every 12 weeks) while expanding into inflammatory bowel disease (IBD) and directly challenging Stelara’s position as biosimilar dynamics intensify.

For the investment trending, please visit our latest exclusive coverage on J.P. Morgan Healthcare Conference in 2026: English Link; Chinese Link

Author

Oscar Wu

讓生醫資訊更加流通與透明化。